Tools for Practice Outils pour la pratique


#397 Meds for Essential Tremor: Steady solution or shaky science?


CLINICAL QUESTION
QUESTION CLINIQUE
How effective are beta-blockers and other first line agents for essential tremor?


BOTTOM LINE
RÉSULTAT FINAL
Older, small randomized controlled trials (RCTs) show that propranolol improves tremor severity (~2-points more than placebo on 10–15-point scales) and leads to feeling “definitely better” in 64-100% versus 14-20% (placebo) at 2-6 weeks. Benefit is seen from 90 mg/day, with 120–240 mg/day most studied. Primidone and topiramate may improve function based on limited RCTs.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • Results statistically significant unless stated.
  • Systematic reviews of patient-oriented outcomes not found. Patient-reported outcomes from double-blind, placebo-controlled RCTs, mainly in upper limb tremor, described here.
  • Propranolol:
    • Tremor (patient-rated): 9 of 9 RCTs report benefit over placebo. Examples:1-9
      • Proportion of patients “definitely better” at 2-6 weeks:
        • RCT (10 patients): 100% versus 20% placebo, number needed to treat (NNT)=2 (PEER calculation).1
        • RCT (7 patients): 64% versus 14% placebo,2 NNT=2.
      • Severity on 10-15 point scales (baseline scores not provided). At 2-3 weeks:
        • Three RCTs (9-23 patients): Placebo score 5-12 points. Propranolol ~1.6-2.0 points better than placebo, likely clinically meaningful. Two RCTs statistically different; one not.3-5
    • Function: No difference.6
  • Sotalol: Two RCTs (9-17 patients).
    • Tremor (scale: 0-100, baseline: 34): At 14 days, placebo score: 31. Sotalol: 9 points better than placebo, likely clinically meaningful.10 Other RCT similar.3
  • Metoprolol, atenolol:
    • Symptoms: No difference from placebo.3,5,9,10
    • Metoprolol: Inferior to propranolol.5,11 Example: At 14 days, metoprolol tremor score 4.8 on 10-point scale. Propranolol 1.5 points better.
  • Primidone: Two RCTs (22 patients each).12,13
    • Functional rating (lower=better function, baseline=8). After four weeks, placebo score=7.8 on 15-point scale. Primidone 2.6 points lower (statistics not reported), likely clinically meaningful.
  • Topiramate: Largest RCT (223 patients).14
    • “Good/very good outcome:” 69% versus 15% placebo, NNT=3.
  • Limitations:
    • Many RCTs/systematic reviews report tremor amplitude/frequency but clinical significance unclear.15
      • Patient and clinician-rated symptom improvement differ.
    • Numerous symptom scales (many unvalidated), frequent incomplete reporting.

CONTEXT
CONTEXTE
  • Guidelines: Propranolol, topiramate and primidone first-line.16,17
    • Options: Alprazolam,18 gabapentinoids (inconsistent benefit),6,19-23 botulinum toxin.24
  • Propranolol dosing:
    • Lower doses (possibly as low as 90mg/day) similarly effective to higher (320mg)2,4,5
    • “As needed”: No RCTs.


b keith comeau September 15, 2025

Well done. Thank you

Nirmit Sheth October 1, 2025

Interesting

Jeremy Keller October 5, 2025

I often do not start at this high a dose of propranolol

Sameena Shah November 1, 2025

very useful


Latest Tools for Practice
Derniers outils pour la pratique

#403 A Whiff of Prevention: Treating Male Partners to Reduce Bacterial Vaginosis Recurrence

Does treating male sexual partners of females undergoing treatment for bacterial vaginosis infection decrease recurrence?
Read Lire 0.25 credits available Crédits disponibles

#402 Nipple Confusion or Nonsense? Pacifiers and Breastfeeding Duration

In term infants, does restricting early use of pacifiers result in higher rates of breastfeeding up to 6 months of age?
Read Lire 0.25 credits available Crédits disponibles

#401 Vape Expectations: Are electronic cigarettes the real deal for smoking cessation? (Update)

Are nicotine-containing e-cigarettes more effective than other available options for smoking cessation?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Allison Paige MD CCFP
  • Samantha S. Moe PharmD ACRP

1. Tolosa ES, Loewenson RB. Neurology 1975; Nov;25(11):1041-4.

2. Morgan M, Langton Hewer R, Cooper R. J Neurol Neurosurg Psychiatry. 1973 Aug;36(4):618-24

3. Jefferson D, Jenner P, Marsden CD. J Neurol Neurosurg Psychiatry. 1979; Oct;42(10):904-9.

4. Cleeves L, Findley LJ. J Neurol Neurosurg Psychiatry. 1988 Mar;51(3):379-84

5. Calzetti S, Findley LJ, Perucca E, et al. J Neurol Neurosurg Psychiatry. 1982 Oct;45(10):893-7.

6. Gironell A, Kulisevsky J, Barbanoj M et al. Arch Neurol. 1999 Apr;56(4): 475-80.

7. Teravainen H, Huttunen J, Larsen TA. Acta Neurol Scand. 1986 Jul;74(1):34-7.

8. Winkler GF, Young RR. N Engl J Med. 1974 May 2;290: 984-88.

9. Larsen TA, Teravainen H, Calne DB. Acta Neurol Scandinav. 1982 Nov;66:547-554.

10. Leigh PN, Jefferson D, Twomey A, et al. J Neurol Neurosurg Psychiatry. 1983 Aug;46(8): 710-5.

11. Larsen TA, Teravainen H. Adv Neurol. 1983;37:247-251.

12. Gunal DI, Afsar N, Bekiroglu N, et al. Neurol Sci. 2000 Oct;21(5): 315-7.

13. Findley LJ, Cleeves L, Calzetti S. J Neurol Neurosurg Psychiatry. 1985 Sep;48(9):911-915.

14. Ondo WG, Jankovic J, Connor GS, et al. Neurology 2006 Mar 14;66(5):672-7.

15. Zhang, JJ, Yan R, Cui Y, et al. eClinicalMedicine. 2024 Oct 18;77:102889.

16. Ferreira JJ, Mestre TA, Lyons KE, et al. Mov Disord. 2019 Jul;34(7): 950-8.

17. Zappia M, Albanese A, Bruno E, et al. J Neurol. 2013 Mar;260(3):714-40.

18. Bruno E, Nicoletti A, Quattrocchi G et al. Cochrane Database Syst Rev. 2015 Dec 6;2015(205(12):CD009681.

19. Pahwa R, Lyons K, Hubble JP, et al. Mov Disord. 1988 May;13(3): 465-7.

20. Ondo W, Hunter C, Vuong KD, et al. Mov Disord. 2000 Jul;15(4): 678-82.

21. Ferrara JM, Kenney C, Davidson AL, et al. J Neurol Sci. 2009 Oct 15;285(1-2): 195-7.

22. Zesiewicz TA, Sullivan KL, Hinson V, et al. Mov Disord. 2013 Feb;28(2):249-50.

23. Zesiewicz TA, Ward CL, Hauser RA, et al. Mov Disord. 2007 Aug 15;22(11):1660-3.

24. Brin MF, Kyons KE, Doucette J, et al. Neurology. 2001 Jun 12;56(11):1523-8.

Authors do not have any conflicts of interest to declare.